Interventions
What studies found when biomarkers were changed.
304 catalogued effects of drugs, diet, exercise and other interventions on specific biomarkers, each linked to its source. They describe study results, not recommendations.
| Biomarker | Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|---|
| Alanine Aminotransferase (ALT) | diet | Weight loss (5-10% body weight) and avoidance of ultra-processed foods/fructose | Reduces elevated ALT by 40-60% into normal range (<25 U/L) | RCT | Kunutsor SK, et al. Liver enzymes and risk of all-cause and cardiovasc… |
| Alanine Aminotransferase (ALT) | diet | Weight loss (7-10% body weight) and fructose restriction | -30% to -60% reduction (drop to normal range) | rct | Vilar-Gomez E, et al. Gastroenterology. 2015;149:367-378.… |
| Alanine Aminotransferase (ALT) | diet | Daily filtered black coffee consumption (2-3 cups/day) | -15% to -25% reduction | meta-analysis | Kennedy OJ, et al. Aliment Pharmacol Ther. 2016;43:562-574.… |
| Alanine Aminotransferase (ALT) | diet | Excessive acute or chronic ethanol consumption | +100% to +400% elevation | clinical guideline | European Association for the Study of the Liver. J Hepatol. 2018;69:15… |
| Alanine Aminotransferase (ALT) | pharmacologic | Pioglitazone or GLP-1 RA therapy in MASLD/NASH | -35% to -55% reduction | rct | Sanyal AJ, et al. N Engl J Med. 2010;362:1675-1685.… |
| Alanine Aminotransferase (ALT) | pharmacologic | Acetaminophen overdose or hepatotoxic drug-induced liver injury (DILI) | +500% to +5000% acute elevation (>1000 U/L) | clinical guideline | Chalasani NP, et al. Am J Gastroenterol. 2021;116:878-898.… |
| Alkaline Phosphatase (ALP) | clinical | Biliary ductal obstruction, choledocholithiasis, or primary sclerosing cholangitis | +200% to +800% elevation (>250 U/L) | clinical guideline | Hirschfield GM, et al. Lancet. 2013;381:1579-1588.… |
| Alkaline Phosphatase (ALP) | clinical | Active Paget's disease of bone or osteolytic bone metastases | +300% to +1200% elevation | clinical guideline | Ralston SH, et al. J Bone Miner Res. 2019;34:579-604.… |
| Alkaline Phosphatase (ALP) | nutraceutical | Optimization of Vitamin D and dietary Calcium homeostasis | -15% to -25% reduction in secondary hyperparathyroid ALP elevations | meta-analysis | Holick MF. N Engl J Med. 2007;357:266-281.… |
| Alkaline Phosphatase (ALP) | pharmacologic | Ursodeoxycholic acid (UDCA 13-15 mg/kg/day) in cholestatic liver diseases | -35% to -65% reduction | rct | Poupon RE, et al. N Engl J Med. 1994;330:1342-1347.… |
| Alkaline Phosphatase (ALP) | pharmacologic | Antiresorptive bisphosphonates (Alendronate / Zoledronic acid) in bone turnover / Paget's disease | -40% to -75% reduction to normal baseline | rct | Reid IR, et al. N Engl J Med. 2005;353:898-908.… |
| Apolipoprotein A1 (ApoA1) | behavioral | Cigarette smoking and chronic tobacco exposure | -15% to -28% reduction | prospective cohort | Garrison RJ, et al. Atherosclerosis. 1978;30:17-25.… |
| Apolipoprotein A1 (ApoA1) | clinical | Severe hypertriglyceridemic metabolic syndrome | -20% to -40% reduction | meta-analysis | Yusuf S, et al. Lancet. 2004;364:937-952.… |
| Apolipoprotein A1 (ApoA1) | diet | Mediterranean dietary pattern rich in polyphenols and virgin olive oil | +6% to +14% increase with enhanced ApoA1 functionality | rct | Babio N, et al. Ann Intern Med. 2014;161:815-824.… |
| Apolipoprotein A1 (ApoA1) | exercise | Aerobic endurance training and vigorous physical activity | +8% to +18% increase | meta-analysis | Leon AS, et al. Med Sci Sports Exerc. 2000;32:1511-1520.… |
| Apolipoprotein A1 (ApoA1) | pharmacologic | Niacin therapy (Extended-release 1000-2000 mg/day) | +15% to +25% increase | rct | Boden WE, et al. N Engl J Med. 2011;365:2255-2267.… |
| Apolipoprotein B (ApoB) | clinical | Familial combined hyperlipidemia and hepatic ApoB overproduction | +40% to +100% elevation (>130 mg/dL) | clinical guideline | Sniderman AD, et al. J Clin Lipidol. 2019;13:706-716.… |
| Apolipoprotein B (ApoB) | diet | Very low saturated fat diet coupled with viscous dietary fibers | -15% to -25% reduction | rct | Jenkins DJ, et al. Am J Clin Nutr. 2003;78:213-221.… |
| Apolipoprotein B (ApoB) | diet | High saturated fatty acid intake and trans fat consumption | +20% to +40% elevation | meta-analysis | Mensink RP, et al. Am J Clin Nutr. 2003;77:1146-1155.… |
| Apolipoprotein B (ApoB) | pharmacologic | High-intensity Statin + Ezetimibe +/- PCSK9 Monoclonal Antibody (Evolocumab/Alirocumab) | Reduces ApoB by 45-75% down to target <60 mg/dL | RCT | Ridker PM, et al. Rosuvastatin to prevent vascular events in men and w… |
| Apolipoprotein B (ApoB) | pharmacologic | PCSK9 monoclonal antibodies (Evolocumab / Alirocumab) | -45% to -55% reduction | rct | Sabatine MS, et al. N Engl J Med. 2017;376:1713-1722.… |
| Apolipoprotein B (ApoB) | pharmacologic | High-intensity statins (Atorvastatin 80mg / Rosuvastatin 40mg) | -35% to -48% reduction | meta-analysis | Boekholdt SM, et al. J Am Coll Cardiol. 2014;64:485-494.… |
| Aspartate Aminotransferase (AST) | behavioral | Ethanol abstinence in alcohol-associated liver disease | -50% to -80% rapid normalization | prospective cohort | Lucey MR, et al. N Engl J Med. 2009;360:2758-2769.… |
| Aspartate Aminotransferase (AST) | clinical | Acute myocardial infarction or ischemic hepatitis ('shock liver') | +500% to +3000% elevation | clinical guideline | Henrion J, et al. Medicine (Baltimore). 2003;82:392-406.… |
| Aspartate Aminotransferase (AST) | diet | Resolution of hepatic steatosis via hypocaloric Mediterranean diet | -25% to -45% reduction | rct | Ryan MC, et al. J Hepatol. 2013;59:138-143.… |
| Aspartate Aminotransferase (AST) | nutraceutical | Vitamin E supplementation (800 IU/day) in non-diabetic NASH | -20% to -35% reduction | rct | Sanyal AJ, et al. N Engl J Med. 2010;362:1675-1685.… |
| Aspartate Aminotransferase (AST) | physiological | Acute rhabdomyolysis or severe unaccustomed eccentric muscle damage | +200% to +1000% transient elevation | systematic review | Pettersson J, et al. Br J Clin Pharmacol. 2008;65:253-259.… |
| Blood Urea Nitrogen (BUN) | clinical | Upper gastrointestinal bleeding and hematoma resorption | +100% to +300% acute elevation (>40 mg/dL) | systematic review | Ernst AA, et al. South Med J. 1999;92:990-994.… |
| Blood Urea Nitrogen (BUN) | diet | Structured dietary protein moderation (0.8-1.0 g/kg body weight) in CKD | -20% to -40% reduction (4-8 mg/dL) | meta-analysis | Kopple JD. J Am Soc Nephrol. 2001;12:2188-2194.… |
| Blood Urea Nitrogen (BUN) | diet | High-protein hypercatabolic diet (>2.5 g/kg/day) with inadequate hydration | +30% to +70% elevation | rct | Martin WF, et al. Nutr Metab (Lond). 2005;2:25.… |
| Blood Urea Nitrogen (BUN) | lifestyle | Optimal fluid and electrolyte intake | -15% to -30% reduction in prerenal azotemia | rct | Sontrop JM, et al. Am J Kidney Dis. 2013;61:847-854.… |
| Blood Urea Nitrogen (BUN) | pharmacologic | Guideline-directed neurohormonal blockade in heart failure (Beta-blockers, ACEi) | -15% to -25% reduction in neurohormonal azotemia | rct | Aronson D, et al. Circulation. 2004;110:3817-3823.… |
| Cardiorespiratory Fitness (VO2 Max) | clinical | Severe chronic obstructive pulmonary disease (COPD) or HFrEF | -40% to -70% impairment (VO2 max < 14 mL/kg/min) | clinical guideline | Mancini DM, et al. Circulation. 1991;83:778-786.… |
| Cardiorespiratory Fitness (VO2 Max) | exercise | High-intensity interval training (HIIT) and high-volume polarized Zone 2 endurance cardio | Increases VO2 Max by 4-8 mL/kg/min (15-25%) | RCT | National Center for Health Statistics. National Health and Nutrition E… |
| Cardiorespiratory Fitness (VO2 Max) | exercise | High-Intensity Interval Training (HIIT 4x4 min @ 90% HRmax) | +4 to +8 mL/kg/min (+12% to +22%) VO2 max increase | meta-analysis | Milanovic Z, et al. Sports Med. 2015;45:1469-1481.… |
| Cardiorespiratory Fitness (VO2 Max) | exercise | High-volume polarized aerobic base training (Zone 2 endurance) | +3 to +7 mL/kg/min increase; enhanced mitochondrial density | rct | Stoggl T, et al. Front Physiol. 2014;5:33.… |
| Cardiorespiratory Fitness (VO2 Max) | lifestyle | Sedentary lifestyle and continuous physical inactivity | -10% per decade baseline decline (accelerates with inactivity) | prospective cohort | Mandsager K, et al. JAMA Netw Open. 2018;1:e183605.… |
| Cardiorespiratory Fitness (VO2 Max) | nutraceutical | Dietary inorganic nitrate / Beetroot juice supplementation | +1 to +3 mL/kg/min acute increase in peak power / exercise economy | meta-analysis | Jones AM. Sports Med. 2014;44:S35-S45.… |
| Carotid-Femoral Pulse Wave Velocity (PWV) | behavioral | Chronic heavy cigarette smoking | +1.0 to +2.5 m/s elevation via elastin degradation | meta-analysis | Vlachopoulos C, et al. J Am Coll Cardiol. 2010;55:1318-1327.… |
| Carotid-Femoral Pulse Wave Velocity (PWV) | clinical | Advanced vascular calcification in chronic kidney disease / diabetes | +2.5 to +6.0 m/s elevation (>10.0 m/s, high CV event risk) | prospective cohort | Blacher J, et al. Circulation. 1999;99:2434-2439.… |
| Carotid-Femoral Pulse Wave Velocity (PWV) | diet | Dietary sodium restriction and dietary nitrate / polyphenol supplementation | -0.5 to -1.0 m/s reduction | rct | Juraschek SP, et al. J Am Coll Cardiol. 2017;70:2748-2757.… |
| Carotid-Femoral Pulse Wave Velocity (PWV) | exercise | Lifelong aerobic endurance exercise and blood pressure control | Lowers cfPWV by 1.0-2.0 m/s (equivalent to 10-15 years younger vascular age) | meta-analysis | Rapsomaniki E, et al. Blood pressure and risk of vascular disease: 1.2… |
| Carotid-Femoral Pulse Wave Velocity (PWV) | exercise | Long-term aerobic endurance and cycling / running exercise | -0.8 to -1.8 m/s reduction in arterial stiffness | meta-analysis | Ashor AW, et al. Sports Med. 2014;44:1773-1788.… |
| Carotid-Femoral Pulse Wave Velocity (PWV) | pharmacologic | RAAS inhibitor therapy (ACE inhibitors / ARBs) | -0.7 to -1.5 m/s reduction via vascular remodeling | meta-analysis | Ong KT, et al. J Hypertens. 2011;29:1439-1449.… |
| Diastolic Blood Pressure (DBP) | behavioral | Stress management, slow deep breathing (6 breaths/min), and meditation | -3 to -6 mmHg diastolic reduction | rct | Grossman E, et al. J Hum Hypertens. 2001;15:263-269.… |
| Diastolic Blood Pressure (DBP) | exercise | Aerobic conditioning and 5-10% weight loss | -4 to -8 mmHg diastolic reduction | meta-analysis | Neter JE, et al. Hypertension. 2003;42:878-884.… |
| Diastolic Blood Pressure (DBP) | pharmacologic | Calcium channel blockers (Amlodipine 5-10 mg) / ACE inhibitors | -8 to -14 mmHg diastolic reduction | meta-analysis | Law MR, et al. BMJ. 2009;338:b1665.… |
| Diastolic Blood Pressure (DBP) | pharmacologic | Excessive over-titration of multi-agent vasodilators causing DBP < 55 mmHg | Coronary hypoperfusion and myocardial ischemic injury risk | prospective cohort | Messerli FH, et al. J Am Coll Cardiol. 2006;48:2198-2200.… |
| Diastolic Blood Pressure (DBP) | sleep | Chronic sympathoadrenal stress and poor sleep | +6 to +12 mmHg diastolic elevation | prospective cohort | Gangwisch JE, et al. Hypertension. 2006;47:833-839.… |
| Erythrocyte Sedimentation Rate (ESR) | clinical | Uncontrolled autoimmune flare or untreated chronic infectious foci | +100% to +400% elevation (>50 mm/hr) | clinical guideline | Brigden ML. Am Fam Physician. 1999;60:1443-1450.… |
| Erythrocyte Sedimentation Rate (ESR) | clinical | End-stage renal disease or nephrotic syndrome | +80% to +200% elevation | systematic review | Breda L, et al. Autoimmun Rev. 2010;9:747-750.… |
| Erythrocyte Sedimentation Rate (ESR) | diet | Whole-food plant-predominant anti-inflammatory dietary pattern | Decreases ESR by 5-12 mm/hr in chronic inflammatory cohorts | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Erythrocyte Sedimentation Rate (ESR) | diet | Anti-inflammatory Mediterranean dietary protocol | -15% to -30% reduction | rct | Skoldstam L, et al. Ann Rheum Dis. 2003;62:208-214.… |
| Erythrocyte Sedimentation Rate (ESR) | exercise | Regular moderate physical exercise | -10% to -20% reduction | prospective cohort | Metsios GS, et al. Rheumatology. 2008;47:1800-1804.… |
| Erythrocyte Sedimentation Rate (ESR) | pharmacologic | Glucocorticoids and DMARD anti-inflammatory therapy in active inflammatory disease | -40% to -70% reduction | clinical guideline | Singh JA, et al. Arthritis Care Res. 2016;68:1-25.… |
| Estimated Glomerular Filtration Rate (eGFR) | clinical | Intensive blood pressure normalization (<130/80 mmHg) | -25% reduction in CKD incidence | meta-analysis | Lv J, et al. J Am Soc Nephrol. 2013;24:996-1003.… |
| Estimated Glomerular Filtration Rate (eGFR) | clinical | Chronic uncontrolled Type 2 Diabetes with diabetic glomerulosclerosis | -3 to -8 mL/min/1.73m² annual eGFR loss | prospective cohort | Adler AI, et al. Kidney Int. 2003;63:225-232.… |
| Estimated Glomerular Filtration Rate (eGFR) | pharmacologic | SGLT2 inhibitors and Nonsteroidal Mineralocorticoid Receptor Antagonists (Finerenone) | Significantly attenuates chronic eGFR slope loss by 1.5-2.5 mL/min/1.73m2/year | RCT | Chronic Kidney Disease Prognosis Consortium. Association of estimated … |
| Estimated Glomerular Filtration Rate (eGFR) | pharmacologic | Non-steroidal mineralocorticoid receptor antagonists (Finerenone) | -23% reduction in eGFR decline and kidney failure progression | rct | Bakris GL, et al. N Engl J Med. 2020;383:2219-2229.… |
| Estimated Glomerular Filtration Rate (eGFR) | pharmacologic | SGLT2 inhibitors (Empagliflozin / Canagliflozin) | +30% to +50% preservation of annual eGFR slope | rct | Perkovic V, et al. N Engl J Med. 2019;380:2295-2306.… |
| Estimated Glomerular Filtration Rate (eGFR) | pharmacologic | Chronic heavy exposure to radiocontrast agents or nephrotoxic aminoglycosides | -20% to -50% acute decline in eGFR | systematic review | Marenzi G, et al. N Engl J Med. 2004;351:437-446.… |
| Fasting Plasma Glucose | diet | Low-glycemic Mediterranean or carbohydrate-restricted dietary pattern | Reduces fasting glucose by 15-30 mg/dL and HbA1c by 0.5-1.2% | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Fasting Plasma Glucose | diet | Time-restricted eating and ketogenic carbohydrate restriction | -15 to -30 mg/dL reduction | meta-analysis | Sutton EF, et al. Cell Metab. 2018;27:1212-1221.… |
| Fasting Plasma Glucose | diet | High glycemic load diet and sugar-sweetened beverages | +25 to +60 mg/dL elevation | meta-analysis | Malik VS, et al. Diabetes Care. 2010;33:2477-2483.… |
| Fasting Plasma Glucose | exercise | Post-prandial walking (15-30 min) and progressive resistance training | Reduces acute glucose excursions by 20-35% and baseline fasting glucose by 8-15 mg/dL | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Fasting Plasma Glucose | exercise | Postprandial walking and structured resistance training | -10 to -22 mg/dL reduction | rct | Reynolds AN, et al. Diabetologia. 2016;59:2572-2578.… |
| Fasting Plasma Glucose | pharmacologic | GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) | -25 to -50 mg/dL reduction | rct | Wilding JPH, et al. N Engl J Med. 2021;384:989-1002.… |
| Fasting Plasma Glucose | pharmacologic | Metformin therapy (500-2000 mg/day) | -20 to -40 mg/dL reduction | rct | Knowler WC, et al. N Engl J Med. 2002;346:393-403.… |
| Fasting Plasma Glucose | pharmacologic | Chronic glucocorticoid therapy (Prednisone / Dexamethasone) | +30 to +90 mg/dL steroid-induced hyperglycemia | systematic review | Kwon S, et al. Diabetes Spectr. 2013;26:118-124.… |
| Fasting Plasma Glucose | sleep | Severe obstructive sleep apnea with nocturnal hypoxemia | +15 to +35 mg/dL elevation | prospective cohort | Punjabi NM, et al. Am J Respir Crit Care Med. 2004;169:156-162.… |
| Fasting Serum Insulin | diet | Time-restricted eating (16:8) and reduction of refined starches | Reduces fasting insulin by 30-50% | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Fasting Serum Insulin | diet | Therapeutic intermittent fasting and prolonged fasting (16:8 to 24hr) | -30% to -60% reduction | rct | De Cabo R, et al. N Engl J Med. 2019;381:2541-2551.… |
| Fasting Serum Insulin | diet | Frequent snacking with refined high-glycemic carbohydrates | +40% to +90% basal elevation | rct | Koopman R, et al. Am J Clin Nutr. 2005;82:298-306.… |
| Fasting Serum Insulin | exercise | Intensive resistance hypertrophy training | -20% to -40% reduction via GLUT4 non-insulin mediated uptake | meta-analysis | Jalo E, et al. Sports Med. 2022;52:2789-2811.… |
| Fasting Serum Insulin | lifestyle | Excessive visceral fat accretion and hepatic steatosis | +100% to +300% elevation (fasting insulin > 15 µIU/mL) | prospective cohort | Kahn SE, et al. Nature. 2006;444:840-846.… |
| Fasting Serum Insulin | pharmacologic | SGLT2 inhibitors (Empagliflozin / Dapagliflozin) | -15% to -30% reduction via glucosuria and beta-cell resting | rct | Ferrannini E, et al. Diabetes Care. 2014;37:2084-2090.… |
| Fibrinogen | behavioral | Smoking cessation | Lowers plasma fibrinogen by 30-50 mg/dL within 6-12 months | cohort | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Fibrinogen | behavioral | Cessation of cigarette smoking | -15% to -25% normalization within 12 months | prospective cohort | Tuut M, et al. Atherosclerosis. 1996;126:125-132.… |
| Fibrinogen | behavioral | Cigarette smoking and chronic tobacco inhalation | +20% to +45% elevation | meta-analysis | Bembich S, et al. Thromb Haemost. 2004;92:699-707.… |
| Fibrinogen | environmental | High particulate air pollution exposure (PM2.5) | +10% to +25% elevation | prospective cohort | Pope CA 3rd, et al. Circulation. 2004;109:71-77.… |
| Fibrinogen | exercise | Regular moderate aerobic endurance exercise | -10% to -20% reduction (30-50 mg/dL) | meta-analysis | Ernst E. Thromb Res. 1993;70:271-274.… |
| Fibrinogen | pharmacologic | Fibrate therapy (Fenofibrate 145-200 mg/day) | -12% to -20% reduction | rct | Rosenson RS. Atherosclerosis. 2007;190:407-411.… |
| Gamma-Glutamyl Transferase (GGT) | behavioral | Cessation or drastic reduction of alcohol intake and coffee consumption (2-3 cups/day) | Lowers serum GGT by 30-65% within 4-8 weeks | cohort | Kunutsor SK, et al. Liver enzymes and risk of all-cause and cardiovasc… |
| Gamma-Glutamyl Transferase (GGT) | behavioral | Complete alcohol abstinence in heavy drinkers | -40% to -70% reduction within 4-8 weeks | prospective cohort | Whitfield JB. Crit Rev Clin Lab Sci. 2001;38:263-355.… |
| Gamma-Glutamyl Transferase (GGT) | diet | High dietary antioxidant intake and regular coffee consumption | -15% to -30% reduction | meta-analysis | Xiao Q, et al. Hepatology. 2014;60:2020-2030.… |
| Gamma-Glutamyl Transferase (GGT) | diet | Chronic heavy alcohol consumption | +150% to +600% elevation (>80 U/L) | meta-analysis | Conigrave KM, et al. Addiction. 2002;97:1429-1437.… |
| Gamma-Glutamyl Transferase (GGT) | nutraceutical | Glutathione / N-Acetylcysteine (NAC 1200 mg/day) supplementation | -10% to -25% reduction | rct | Khoshbaten M, et al. Hepat Mon. 2010;10:12-16.… |
| Gamma-Glutamyl Transferase (GGT) | pharmacologic | Enzyme-inducing anticonvulsants (Phenytoin, Carbamazepine, Phenobarbital) | +50% to +200% elevation without liver damage | clinical guideline | Luoma PV, et al. Acta Med Scand. 1982;211:423-426.… |
| Glycated Hemoglobin (HbA1c) | clinical | Progressive beta-cell failure and unmanaged insulin resistance | +1.5% to +4.5% absolute elevation (HbA1c > 8.0%) | clinical guideline | American Diabetes Association. Diabetes Care. 2023;46:S19-S40.… |
| Glycated Hemoglobin (HbA1c) | diet | Low-carbohydrate / Ketogenic dietary intervention | -0.8% to -1.5% absolute HbA1c reduction | meta-analysis | Goldenberg JZ, et al. BMJ. 2021;372:m4743.… |
| Glycated Hemoglobin (HbA1c) | diet | Chronic high-glycemic ultra-processed dietary pattern | +0.5% to +1.2% elevation | prospective cohort | Srour B, et al. JAMA Intern Med. 2020;180:283-291.… |
| Glycated Hemoglobin (HbA1c) | exercise | Combined aerobic and resistance training (3x/week) | -0.5% to -0.9% absolute HbA1c reduction | meta-analysis | Church TS, et al. JAMA. 2010;304:2253-2262.… |
| Glycated Hemoglobin (HbA1c) | lifestyle | Intensive lifestyle intervention (Diabetes Prevention Program) | -0.6% to -1.2% absolute reduction; 58% diabetes risk reduction | rct | Knowler WC, et al. N Engl J Med. 2002;346:393-403.… |
| Glycated Hemoglobin (HbA1c) | pharmacologic | GLP-1 Receptor Agonists (Semaglutide/Tirzepatide) or Metformin | Lowers HbA1c by 1.0-2.4% and induces significant weight loss | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Glycated Hemoglobin (HbA1c) | pharmacologic | Dual GIP/GLP-1 receptor agonist (Tirzepatide 5-15mg) | -1.8% to -2.6% absolute HbA1c reduction | rct | Frias JP, et al. N Engl J Med. 2021;385:503-515.… |
| HDL Cholesterol | behavioral | Smoking cessation | +4 to +8 mg/dL increase within 6-12 weeks | meta-analysis | Maeda K, et al. Circ J. 2003;67:402-406.… |
| HDL Cholesterol | diet | Mediterranean diet rich in monounsaturated fats (Extra Virgin Olive Oil) | +3 to +7 mg/dL increase with improved HDL particle functionality | rct | Hernaez A, et al. Circulation. 2017;135:633-643.… |
| HDL Cholesterol | exercise | High-intensity aerobic intervals and endurance training | Increases HDL-C by 3-6 mg/dL (5-10%) and enhances cholesterol efflux capacity | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| HDL Cholesterol | exercise | Vigorous aerobic endurance and high-intensity interval exercise | +5 to +10 mg/dL (+8% to +18%) increase | meta-analysis | Kodama S, et al. Arch Intern Med. 2007;167:999-1008.… |
| HDL Cholesterol | lifestyle | Severe insulin resistance and visceral adiposity | -20% to -40% reduction (drop <35 mg/dL) | prospective cohort | Grundy SM. Circulation. 2004;109:433-438.… |
| HDL Cholesterol | pharmacologic | Anabolic-androgenic steroid abuse | -50% to -90% profound suppression (often <15 mg/dL) | prospective cohort | Baggish AL, et al. Circulation. 2017;135:1997-2007.… |
| Hemoglobin Concentration | clinical | Chronic occult gastrointestinal blood loss (Colorectal lesion / PUD) | -3.0 to -8.0 g/dL severe anemia (<8.0 g/dL) | clinical guideline | Goddard AF, et al. Gut. 2011;60:1309-1316.… |
| Hemoglobin Concentration | clinical | Polycythemia vera (JAK2 V617F mutation) or severe chronic hypoxia | +4.0 to +8.0 g/dL dangerous hyperviscosity (>18.5 g/dL) | clinical guideline | Tefferi A, et al. Am J Hematol. 2018;93:1424-1441.… |
| Hemoglobin Concentration | exercise | Altitude / hypoxic conditioning protocol | +0.5 to +1.2 g/dL physiological increase | rct | Levine BD, et al. J Appl Physiol. 1997;83:102-112.… |
| Hemoglobin Concentration | nutraceutical | Intravenous / oral iron repletion in iron deficiency anemia | +2.0 to +4.0 g/dL normalization | meta-analysis | Auerbach M, et al. Am J Hematol. 2016;91:31-38.… |
| Hemoglobin Concentration | pharmacologic | Erythropoiesis-stimulating agents (ESA) / HIF-PH inhibitors (Roxadustat) in CKD anemia | +1.5 to +3.0 g/dL target correction (aiming for 10-11.5 g/dL) | rct | Chen N, et al. N Engl J Med. 2019;381:1001-1010.… |
| Hemoglobin Concentration | supplement | Targeted elemental iron or erythropoiesis-stimulating cofactors when deficient | Normalizes hemoglobin to optimal 13.5-16.5 g/dL (men) and 12.0-15.0 g/dL (women) | RCT | National Center for Health Statistics. National Health and Nutrition E… |
| High-Sensitivity C-Reactive Protein (hs-CRP) | clinical | Severe Periodontitis and Chronic Gum Infection | +40% to +80% elevation | systematic review | Paraskevas S, et al. J Clin Periodontol. 2008;35:277-291.… |
| High-Sensitivity C-Reactive Protein (hs-CRP) | diet | Mediterranean Diet enriched with Extra-Virgin Olive Oil or Tree Nuts | Reduces hs-CRP by 15-25% over 12 months | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| High-Sensitivity C-Reactive Protein (hs-CRP) | diet | Mediterranean Diet rich in extra virgin olive oil and nuts | -20% to -35% reduction | rct | Estruch R, et al. N Engl J Med. 2018;378:e34.… |
| High-Sensitivity C-Reactive Protein (hs-CRP) | diet | High Ultra-Processed Food and Refined Sugar Consumption | +30% to +60% elevation | prospective cohort | Srour B, et al. BMJ. 2019;365:l1451.… |
| High-Sensitivity C-Reactive Protein (hs-CRP) | exercise | Aerobic and resistance exercise training (>= 150 min/week moderate-vigorous) | Reduces hs-CRP by 18-30% | meta-analysis | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| High-Sensitivity C-Reactive Protein (hs-CRP) | exercise | High-intensity interval and continuous aerobic exercise | -15% to -30% reduction | meta-analysis | Fedewa MV, et al. Br J Sports Med. 2017;51:670-676.… |
| High-Sensitivity C-Reactive Protein (hs-CRP) | nutraceutical | Curcumin Phytosome formulation (1000 mg/day) | -15% to -25% reduction | meta-analysis | Sahebkar A. Clin Nutr. 2014;33:418-425.… |
| High-Sensitivity C-Reactive Protein (hs-CRP) | pharmacologic | Statin therapy (e.g., Rosuvastatin 20 mg/day or Atorvastatin) | Reduces hs-CRP by 37% (from median 4.2 to 2.2 mg/L) | RCT | Ridker PM, et al. Rosuvastatin to prevent vascular events in men and w… |
| High-Sensitivity C-Reactive Protein (hs-CRP) | pharmacologic | Statin therapy (Atorvastatin 40-80 mg or Rosuvastatin 20 mg) | -37% to -52% reduction | rct | Ridker PM, et al. N Engl J Med. 2008;359:2195-2207.… |
| High-Sensitivity C-Reactive Protein (hs-CRP) | sleep | Chronic sleep deprivation (< 6 hours/night) and circadian disruption | Increases circulating hs-CRP by 20-45% | cohort | National Center for Health Statistics. National Health and Nutrition E… |
| High-Sensitivity C-Reactive Protein (hs-CRP) | sleep | Chronic Sleep Deprivation (<5 hours/night) | +25% to +45% elevation | meta-analysis | Irwin MR, et al. Biol Psychiatry. 2016;80:40-52.… |
| High-Sensitivity Cardiac Troponin T (hs-cTnT) | clinical | Early coronary revascularization (PCI / CABG) in acute coronary syndrome | Halts ongoing myocyte necrosis; accelerates clearance | rct | Mehta SR, et al. N Engl J Med. 2009;361:2165-2176.… |
| High-Sensitivity Cardiac Troponin T (hs-cTnT) | clinical | Acute Myocardial Infarction (Type 1 or Type 2 ischemia) | +500% to +10000% acute dynamic rise (>50-1000 ng/L) | clinical guideline | Thygesen K, et al. Circulation. 2018;138:e618-e651.… |
| High-Sensitivity Cardiac Troponin T (hs-cTnT) | lifestyle | Intensive blood pressure reduction and left ventricular hypertrophy regression | -10% to -25% reduction | prospective cohort | McEvoy JW, et al. Circulation. 2015;132:2317-2325.… |
| High-Sensitivity Cardiac Troponin T (hs-cTnT) | pharmacologic | Intensive blood pressure control (<120 mmHg SBP) and statin cardioprotection | Lowers hs-cTnT by 15-30% toward baseline non-detectable levels (<6 ng/L) | RCT | Rapsomaniki E, et al. Blood pressure and risk of vascular disease: 1.2… |
| High-Sensitivity Cardiac Troponin T (hs-cTnT) | pharmacologic | Long-term Cardioprotective Beta-Blockers and ACEi/ARB in structural heart disease | -15% to -35% reduction in chronic baseline hs-TnT leak | meta-analysis | Latini R, et al. Circulation. 2007;116:1242-1249.… |
| High-Sensitivity Cardiac Troponin T (hs-cTnT) | pharmacologic | Acute viral myocarditis or anthracycline chemotherapy cardiotoxicity | +100% to +1500% elevation | systematic review | Cardinale D, et al. Circulation. 2006;114:2474-2481.… |
| Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | exercise | High-intensity resistance training combined with aerobic exercise | Improves HOMA-IR index by 30-45% | meta-analysis | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | exercise | High-intensity interval training (HIIT) combined with resistance training | -25% to -45% reduction | meta-analysis | Batacan RB Jr, et al. Br J Sports Med. 2017;51:494-503.… |
| Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | lifestyle | 10% Total Body Weight Loss through lifestyle modification | -35% to -55% reduction | rct | Petersen KF, et al. Science. 2007;300:1140-1142.… |
| Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | lifestyle | Severe visceral adiposity and physical inactivity | +100% to +350% elevation (HOMA-IR > 3.0) | prospective cohort | Bonora E, et al. Diabetes Care. 2002;25:1135-1141.… |
| Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | pharmacologic | GLP-1 / GIP receptor agonists (Tirzepatide / Semaglutide) | -40% to -65% reduction | rct | Jastreboff AM, et al. N Engl J Med. 2022;387:205-216.… |
| Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | pharmacologic | Atypical antipsychotics (Olanzapine / Clozapine) | +50% to +120% elevation in insulin resistance | meta-analysis | Rummel-Kluge C, et al. Schizophr Res. 2010;123:225-233.… |
| Interleukin-6 (IL-6) | behavioral | Chronic Psychosocial Stress and Elevated Glucocorticoids | +35% to +60% elevation | prospective cohort | Steptoe A, et al. Brain Behav Immun. 2007;21:901-912.… |
| Interleukin-6 (IL-6) | exercise | Regular moderate aerobic endurance training and resistance training | Lowers baseline circulating IL-6 by 20-35% | meta-analysis | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Interleukin-6 (IL-6) | exercise | Structured resistance and moderate aerobic training | -15% to -30% resting reduction | meta-analysis | Zheng G, et al. Cytokine. 2019;117:1-10.… |
| Interleukin-6 (IL-6) | lifestyle | Visceral Adiposity Accumulation (waist circumference >102cm) | +50% to +100% elevation | prospective cohort | Fontana L, et al. Diabetes. 2007;56:1010-1013.… |
| Interleukin-6 (IL-6) | nutraceutical | Omega-3 polyunsaturated fatty acids (EPA/DHA 2-4g/day) | -12% to -22% reduction | meta-analysis | Li K, et al. Mol Nutr Food Res. 2014;58:2116-2125.… |
| Interleukin-6 (IL-6) | pharmacologic | Anti-IL-6 receptor monoclonal antibody (Tocilizumab) | -60% to -80% signaling suppression | rct | Ridker PM, et al. Lancet. 2012;379:1205-1213.… |
| LDL Cholesterol | clinical | Familial hypercholesterolemia gene mutations (LDLR / APOB) | +100% to +300% severe elevation (>190-400 mg/dL) | clinical guideline | Nordestgaard BG, et al. Eur Heart J. 2013;34:3478-3490.… |
| LDL Cholesterol | diet | High soluble viscous fiber intake (>= 10-15g/day psyllium, oats, beta-glucan) | Reduces LDL-C by 5-12 mg/dL (5-10%) | meta-analysis | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| LDL Cholesterol | diet | Portfolio Diet (Plant sterols, soy protein, viscous fiber, almonds) | -20% to -30% reduction | rct | Jenkins DJ, et al. JAMA. 2011;306:831-839.… |
| LDL Cholesterol | diet | Excessive intake of refined saturated fats and palm/coconut oils | +20% to +45% elevation | systematic review | Sacks FM, et al. Circulation. 2017;136:e1-e23.… |
| LDL Cholesterol | pharmacologic | HMG-CoA reductase inhibitors (Statins) / PCSK9 Inhibitors / Ezetimibe | Reduces LDL-C by 30-65% (40-90 mg/dL) | RCT | Ridker PM, et al. Rosuvastatin to prevent vascular events in men and w… |
| LDL Cholesterol | pharmacologic | PCSK9 inhibitors (Evolocumab / Alirocumab) | -50% to -65% reduction | rct | Sabatine MS, et al. N Engl J Med. 2017;376:1713-1722.… |
| LDL Cholesterol | pharmacologic | High-intensity statins plus Ezetimibe 10 mg combination therapy | -55% to -70% reduction | rct | Cannon CP, et al. N Engl J Med. 2015;372:2387-2397.… |
| Lipoprotein(a) [Lp(a)] | clinical | Genetically low LPA Kringle IV type 2 copy number variants | +200% to +1000% inherited elevation (>100 mg/dL) | prospective cohort | Clarke R, et al. N Engl J Med. 2009;361:2518-2528.… |
| Lipoprotein(a) [Lp(a)] | pharmacologic | Novel RNA-targeting therapeutics (Pelacarsen, Olpasiran) or PCSK9 inhibitors | Reduces circulating Lp(a) by 20-30% (PCSK9i) up to 80-95% (siRNA/ASO) | RCT | Ridker PM, et al. Rosuvastatin to prevent vascular events in men and w… |
| Lipoprotein(a) [Lp(a)] | pharmacologic | Antisense oligonucleotide / siRNA inhibitors (Pelacarsen / Olpasiran) | -70% to -95% profound reduction | rct | O'Donoghue ML, et al. N Engl J Med. 2022;387:1855-1864.… |
| Lipoprotein(a) [Lp(a)] | pharmacologic | PCSK9 monoclonal antibodies (Evolocumab / Alirocumab) | -25% to -35% reduction | meta-analysis | Bittner VA, et al. J Am Coll Cardiol. 2020;75:133-144.… |
| Lipoprotein(a) [Lp(a)] | pharmacologic | Niacin therapy (Extended release 1500-2000 mg) | -20% to -30% reduction | rct | Carlson LA. J Intern Med. 2005;258:94-114.… |
| Lipoprotein(a) [Lp(a)] | physiological | Postmenopausal hormone depletion and estrogen deficiency | +15% to +30% elevation post-menopause | prospective cohort | Kimak E, et al. Clin Biochem. 2008;41:744-749.… |
| Maximal Grip Strength | clinical | Severe protein malnutrition and cancer cachexia syndrome | -30% to -60% loss (grip strength < 16-26 kg) | clinical guideline | Cruz-Jentoft AJ, et al. Age Ageing. 2019;48:16-31.… |
| Maximal Grip Strength | exercise | Progressive resistance training (2-4x/week compound barbell/dumbbell movements) | Increases grip and whole-body muscular strength by 15-35% | RCT | National Center for Health Statistics. National Health and Nutrition E… |
| Maximal Grip Strength | exercise | Progressive whole-body resistance training (Heavy compound lifting) | +5 to +12 kg (+15% to +35%) strength increase | meta-analysis | Peterson MD, et al. Ageing Res Rev. 2010;9:226-237.… |
| Maximal Grip Strength | lifestyle | Prolonged bed rest, immobilization, and neuromuscular disuse | -10% to -25% loss within 2-3 weeks | rct | Kortebein P, et al. JAMA. 2007;297:1772-1774.… |
| Maximal Grip Strength | nutraceutical | Optimized protein intake (1.6 g/kg/day) + Creatine monohydrate (5g/day) | +2 to +5 kg additional strength accretion | meta-analysis | Devries MC, et al. J Food Sci. 2014;79:M134-M142.… |
| Maximal Grip Strength | pharmacologic | Testosterone replacement therapy in hypogonadal sarcopenic men | +3 to +7 kg strength increase | rct | Snyder PJ, et al. N Engl J Med. 2016;374:611-624.… |
| N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) | clinical | Acute decompensated congestive heart failure | +300% to +3000% elevation (>1000-5000 pg/mL) | clinical guideline | Januzzi JL Jr, et al. J Am Coll Cardiol. 2018;71:1191-1200.… |
| N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) | clinical | Severe pulmonary arterial hypertension and right ventricular strain | +200% to +1000% elevation | prospective cohort | Fijalkowska A, et al. Circulation. 2006;114:1637-1645.… |
| N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) | lifestyle | Dietary sodium restriction (<2000 mg/day) and structured cardiac rehabilitation | -15% to -30% reduction | rct | O'Connor CM, et al. JAMA. 2009;301:1439-1450.… |
| N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) | pharmacologic | ARNI (Sacubitril/Valsartan), SGLT2 inhibitors, and Beta-blocker guideline-directed medical therapy | Reduces NT-proBNP by 30-50% | RCT | Rapsomaniki E, et al. Blood pressure and risk of vascular disease: 1.2… |
| N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) | pharmacologic | Angiotensin Receptor-Neprilysin Inhibitor (Sacubitril/Valsartan) | -30% to -50% reduction with 20% CV mortality reduction | rct | McMurray JJ, et al. N Engl J Med. 2014;371:993-1004.… |
| N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) | pharmacologic | SGLT2 inhibitors (Empagliflozin / Dapagliflozin) in Heart Failure (HFrEF/HFpEF) | -20% to -35% reduction | rct | Packer M, et al. N Engl J Med. 2020;383:1413-1424.… |
| Neutrophil-to-Lymphocyte Ratio (NLR) | behavioral | Comprehensive stress reduction and mindfulness-based stress intervention | -10% to -25% reduction | rct | Black DS, et al. Psychoneuroendocrinology. 2016;63:342-351.… |
| Neutrophil-to-Lymphocyte Ratio (NLR) | clinical | Severe Sepsis, Acute Bacterial Infection, or Critical Care Shock | +150% to +500% elevation (NLR > 5.0) | meta-analysis | Zahorec R. Bratisl Lek Listy. 2001;102:5-14.… |
| Neutrophil-to-Lymphocyte Ratio (NLR) | exercise | Supervised combined endurance and resistance exercise | Reduces NLR by 0.3-0.7 toward optimal reference (<2.0) | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Neutrophil-to-Lymphocyte Ratio (NLR) | exercise | Aerobic endurance training and cardiovascular conditioning | -15% to -30% reduction towards optimal ratio | rct | Nieman DC, et al. Sports Med. 2019;49:29-37.… |
| Neutrophil-to-Lymphocyte Ratio (NLR) | nutraceutical | Anti-inflammatory botanical extracts (Green Tea EGCG / Curcumin) | -10% to -20% reduction | meta-analysis | Farhadi A, et al. Phytomedicine. 2021;85:153549.… |
| Neutrophil-to-Lymphocyte Ratio (NLR) | sleep | Chronic severe psychological burnout and sleep disruption | +25% to +50% elevation | prospective cohort | Gidron Y, et al. Brain Behav Immun. 2020;87:21-23.… |
| Platelet Count | clinical | Essential thrombocythemia (JAK2 / CALR mutations) | +300 to +1000 × 10³/µL extreme thrombocytosis (>600 × 10³/µL) | clinical guideline | Arber DA, et al. Blood. 2016;127:2391-2405.… |
| Platelet Count | clinical | Severe immune thrombocytopenic purpura (ITP) or splenic sequestration | -150 to -280 × 10³/µL severe thrombocytopenia (<30 × 10³/µL) | clinical guideline | Neunert C, et al. Blood Adv. 2019;3:3829-3866.… |
| Platelet Count | nutraceutical | Dietary omega-3 fatty acids (EPA/DHA 2-3g/day) | Reduces platelet hyperactivity and thromboxane generation | meta-analysis | Gao LG, et al. Atherosclerosis. 2013;226:328-334.… |
| Platelet Count | pharmacologic | Aspirin (81-100 mg) / P2Y12 inhibitors (Clopidogrel) for platelet hyperreactivity | Suppresses thromboxane A2 and platelet aggregation by >90% | rct | Antithrombotic Trialists' Collaboration. BMJ. 2002;324:71-86.… |
| Platelet Count | pharmacologic | Thrombopoietin receptor agonists (Eltrombopag / Romiplostim) in immune thrombocytopenia | +50 to +150 × 10³/µL increase to safe hemostatic levels | rct | Cheng G, et al. Lancet. 2011;377:393-402.… |
| Red Cell Distribution Width (RDW) | clinical | Advanced congestive heart failure and cardiorenal syndrome | +2.0% to +5.0% elevation (RDW > 15.5%) | prospective cohort | Felker GM, et al. J Am Coll Cardiol. 2007;50:40-47.… |
| Red Cell Distribution Width (RDW) | clinical | Severe chronic kidney disease with uremic erythrocyte damage | +1.5% to +4.0% elevation | prospective cohort | Solak Y, et al. Am J Nephrol. 2014;39:328-335.… |
| Red Cell Distribution Width (RDW) | diet | Anti-inflammatory dietary intervention rich in antioxidants | -0.4% to -1.0% reduction | rct | Forhecz Z, et al. Am J Cardiol. 2009;104:1550-1555.… |
| Red Cell Distribution Width (RDW) | environmental | Chronic systemic inflammatory state and oxidative erythrocyte membrane fragility | Increases RDW > 14.5% | cohort | Patel KV, et al. Red cell distribution width and mortality in older ad… |
| Red Cell Distribution Width (RDW) | exercise | Regular cardiorespiratory physical exercise training | -0.5% to -1.2% reduction via improved erythrocyte membrane turnover | prospective cohort | Lippi G, et al. Clin Chem Lab Med. 2014;52:e255-e257.… |
| Red Cell Distribution Width (RDW) | nutraceutical | Correction of micronutrient deficiencies (Iron, Vitamin B12, Folate) | -1.5% to -3.0% reduction in anisocytosis | meta-analysis | Green R. Blood. 2017;129:2603-2611.… |
| Red Cell Distribution Width (RDW) | supplement | Correction of micronutrient deficiencies (Iron, Vitamin B12, and Folate repletion) | Normalizes RDW toward <12.5% | RCT | Patel KV, et al. Red cell distribution width and mortality in older ad… |
| Resting Heart Rate (RHR) | diet | Chronic high caffeine / energy drink abuse and high nicotine intake | +10 to +25 bpm elevation and arrhythmia trigger | rct | Svatikova A, et al. JAMA. 2015;314:2079-2082.… |
| Resting Heart Rate (RHR) | exercise | Zone 2 endurance training / Aerobic conditioning (3-5 sessions/week) | Decreases resting heart rate by 8-15 bpm | meta-analysis | Fox CS, et al. Resting heart rate and risk of cardiovascular disease a… |
| Resting Heart Rate (RHR) | exercise | Cardiorespiratory endurance training (Zone 2 aerobic exercise) | -10 to -20 bpm reduction via increased stroke volume and vagal tone | meta-analysis | Cornelissen VA, et al. J Am Heart Assoc. 2013;2:e004473.… |
| Resting Heart Rate (RHR) | lifestyle | Severe physical deconditioning and prolonged bed rest | +15 to +30 bpm elevation | mechanistic | Convertino VA. Exerc Sport Sci Rev. 1997;25:121-140.… |
| Resting Heart Rate (RHR) | pharmacologic | Cardioselective Beta-1 blockers (Metoprolol succinate / Bisoprolol) | -12 to -22 bpm reduction | rct | CIBIS-II Investigators. Lancet. 1999;353:9-13.… |
| Resting Heart Rate (RHR) | pharmacologic | Sinoatrial funny channel inhibitor (Ivabradine 5-7.5 mg) | -10 to -15 bpm reduction without inotropic compromise | rct | Swedberg K, et al. Lancet. 2010;376:875-885.… |
| Serum 25-Hydroxyvitamin D | clinical | Severe intestinal malabsorption (Celiac disease / Bariatric Roux-en-Y surgery) | -50% to -80% drop in circulating 25(OH)D | clinical guideline | Holick MF, et al. J Clin Endocrinol Metab. 2011;96:1911-1930.… |
| Serum 25-Hydroxyvitamin D | diet | Dietary wild fatty fish consumption (Salmon, Mackerel, Sardines) | +5 to +12 ng/mL increase | prospective cohort | Lu Z, et al. J Steroid Biochem Mol Biol. 2007;103:642-644.… |
| Serum 25-Hydroxyvitamin D | environmental | Sensible solar ultraviolet B (UVB) exposure (15-20 min midday during summer) | Synthesizes 10,000-20,000 IU cutaneous cholecalciferol per whole-body exposure | cohort | Garland CF, et al. Meta-analysis of all-cause mortality according to s… |
| Serum 25-Hydroxyvitamin D | environmental | Safe sensible midday solar ultraviolet B (UVB) exposure (15-30 min) | +10 to +25 ng/mL increase seasonally | rct | Holick MF. N Engl J Med. 2007;357:266-281.… |
| Serum 25-Hydroxyvitamin D | lifestyle | Complete sun avoidance, chronic indoor confinement, and lack of supplementation | Severe deficiency (<10-15 ng/mL); doubles all-cause mortality risk | meta-analysis | Garland CF, et al. Am J Public Health. 2014;104:e43-e50.… |
| Serum 25-Hydroxyvitamin D | nutraceutical | Oral Vitamin D3 (Cholecalciferol 2000-5000 IU/day) | +15 to +35 ng/mL increase into optimal range | meta-analysis | Bischoff-Ferrari HA, et al. Am J Clin Nutr. 2006;84:18-28.… |
| Serum 25-Hydroxyvitamin D | supplement | Oral Cholecalciferol (Vitamin D3) supplementation (2000-5000 IU/day) | Increases serum 25(OH)D from deficient levels to optimal 75-125 nmol/L (30-50 ng/mL) | RCT | Garland CF, et al. Meta-analysis of all-cause mortality according to s… |
| Serum Albumin | behavioral | Severe systemic inflammation, chronic heavy alcohol consumption, or protein-energy malnutrition | Decreases serum albumin by 0.5-1.2 g/dL | cohort | Goldwasser P, Feldman J. Association of serum albumin and mortality ri… |
| Serum Albumin | clinical | Intravenous human albumin infusion in cirrhotic spontaneous bacterial peritonitis | -67% reduction in renal impairment and -60% in-hospital mortality | rct | Sort P, et al. N Engl J Med. 1999;341:403-409.… |
| Serum Albumin | clinical | Nephrotic syndrome with heavy proteinuria (>3.5g/24hr) | -30% to -60% reduction (drop <2.5 g/dL) | clinical guideline | Hull RP, et al. Clin J Am Soc Nephrol. 2008;3:526-538.… |
| Serum Albumin | diet | Adequate dietary protein intake (1.2-1.6 g/kg/day) with sufficient caloric density | Increases serum albumin by 0.2-0.4 g/dL in hypoalbuminemic adults | RCT | Goldwasser P, Feldman J. Association of serum albumin and mortality ri… |
| Serum Albumin | diet | Optimal dietary protein intake (1.2-1.6 g/kg/day with essential amino acids) | +0.3 to +0.6 g/dL increase in hypoalbuminemic frail cohorts | rct | Bauer J, et al. J Am Med Dir Assoc. 2013;14:542-559.… |
| Serum Albumin | diet | Severe Protein-Energy Wasting, Cachexia, and Anorexia Nervosa | -20% to -40% reduction (drop <3.5 g/dL) | meta-analysis | Fouque D, et al. Kidney Int. 2008;73:391-398.… |
| Serum Albumin | pharmacologic | Resolution of systemic inflammation via anti-inflammatory therapy | +0.4 to +0.8 g/dL increase as acute phase synthesis normalizes | prospective cohort | Don BR, et al. J Ren Nutr. 2004;14:145-151.… |
| Serum Calcium | clinical | Targeted parathyroidectomy in primary hyperparathyroidism | Permanent curative normalization to 9.2-9.8 mg/dL | clinical guideline | Bilezikian JP, et al. J Clin Endocrinol Metab. 2014;99:3561-3569.… |
| Serum Calcium | clinical | Malignancy-associated hypercalcemia (PTHrP secretion / osteolytic bone mets) | +2.0 to +6.0 mg/dL dangerous hypercalcemia (>12.0 mg/dL) | clinical guideline | Stewart AF. N Engl J Med. 2005;352:373-379.… |
| Serum Calcium | diet | Dietary calcium optimization (1000-1200 mg/day from whole foods) with Vitamin D3 | Restores physiological homeostasis without vascular calcification | meta-analysis | Bolland MJ, et al. BMJ. 2015;351:h4183.… |
| Serum Calcium | nutraceutical | Massive unmonitored Vitamin D intoxication (>50,000 IU/day chronic) | +2.0 to +4.5 mg/dL hypercalcemia and nephrocalcinosis | systematic review | Marcinowska-Suchowierska E, et al. Front Endocrinol. 2018;9:550.… |
| Serum Calcium | pharmacologic | Calcimimetics (Cinacalcet 30-90 mg) in secondary hyperparathyroidism | -0.8 to -1.5 mg/dL reduction to target range | rct | Chertow GM, et al. N Engl J Med. 2004;350:1516-1525.… |
| Serum Creatinine | clinical | Severe dehydration and volume depletion | +30% to +80% prerenal elevation | clinical guideline | KDIGO. Kidney Int Suppl. 2012;2:1-138.… |
| Serum Creatinine | lifestyle | Adequate daily hydration (2.5-3.5 L/day pure water) | -0.1 to -0.3 mg/dL drop via prerenal clearance normalization | rct | Clark WF, et al. JAMA. 2018;319:1870-1879.… |
| Serum Creatinine | pharmacologic | SGLT2 inhibitors (e.g. Empagliflozin, Dapagliflozin) or ACEi/ARB therapy | Preserves long-term renal function, slowing eGFR decline by 40-50% | RCT | Chronic Kidney Disease Prognosis Consortium. Association of estimated … |
| Serum Creatinine | pharmacologic | SGLT2 inhibitors (Empagliflozin / Dapagliflozin) for renal nephron preservation | -30% to -40% reduction in long-term eGFR decline rate | rct | Heerspink HJL, et al. N Engl J Med. 2020;383:1436-1446.… |
| Serum Creatinine | pharmacologic | ACE inhibitors / Angiotensin Receptor Blockers (ARBs) for intraglomerular pressure control | -25% to -35% risk of doubling serum creatinine | rct | Brenner BM, et al. N Engl J Med. 2001;345:861-869.… |
| Serum Creatinine | pharmacologic | High-dose chronic NSAID use (Ibuprofen / Naproxen / Meloxicam) | +20% to +60% elevation via afferent arteriolar vasoconstriction | meta-analysis | Whelton A. Am J Med. 1999;106:13S-24S.… |
| Serum Cystatin C | clinical | Rigorous systolic blood pressure control (<120 mmHg) | -15% to -25% attenuation of filtration decline | rct | SPRINT Research Group. N Engl J Med. 2015;373:2103-2116.… |
| Serum Cystatin C | clinical | Severe untreated hyperthyroidism | +25% to +50% non-renal elevation | prospective cohort | Fricker M, et al. Clin Chem. 2003;49:439-444.… |
| Serum Cystatin C | diet | Optimal plant-dominant dietary protein pattern and blood pressure control | Stabilizes Cystatin C levels and halts progressive rise | cohort | Chronic Kidney Disease Prognosis Consortium. Association of estimated … |
| Serum Cystatin C | lifestyle | Anti-inflammatory Mediterranean lifestyle and exercise | -10% to -18% reduction | prospective cohort | Khatri M, et al. Clin J Am Soc Nephrol. 2014;9:1099-1106.… |
| Serum Cystatin C | pharmacologic | SGLT2 inhibitors (Dapagliflozin / Empagliflozin) | -20% to -35% mitigation of long-term cystatin rise | rct | Wheeler DC, et al. Kidney Int. 2021;100:459-470.… |
| Serum Cystatin C | pharmacologic | Glucocorticoid administration (Prednisone therapy) | +20% to +40% increase independent of actual GFR | mechanistic | Risch L, et al. Clin Chem. 2001;47:2055-2059.… |
| Serum Ferritin | behavioral | Therapeutic phlebotomy / Blood donation in iron overload states | Lowers serum ferritin into optimal 50-150 ug/L range | RCT | National Center for Health Statistics. National Health and Nutrition E… |
| Serum Ferritin | clinical | Therapeutic phlebotomy / regular voluntary blood donation in iron overload | -30% to -60% reduction (50-100 ng/mL drop per unit) | rct | Houschyar KS, et al. BMC Med. 2012;10:54.… |
| Serum Ferritin | clinical | Genetic Hemochromatosis (HFE C282Y mutation homozygosity) | +300% to +1000% elevation (>800 ng/mL) | clinical guideline | Bacon BR, et al. Hepatology. 2011;54:328-343.… |
| Serum Ferritin | diet | Dietary restriction of heme iron and red meat intake | -15% to -35% reduction in hyperferritinemic states | rct | Fleming DJ, et al. Am J Clin Nutr. 2002;76:1375-1384.… |
| Serum Ferritin | nutraceutical | Oral iron supplementation (Ferrous sulfate / bisglycinate) in iron deficiency | +20 to +50 ng/mL increase from deficient baseline | meta-analysis | Stoffel NU, et al. Lancet Haematol. 2017;4:e524-e533.… |
| Serum Ferritin | nutraceutical | High-dose chronic unmonitored iron supplementation | +100% to +300% elevation causing tissue hemosiderosis | prospective cohort | Sullivan JL. Lancet. 1981;1:1293-1294.… |
| Serum Phosphate | clinical | Optimization of dialytic phosphate clearance in ESRD | -1.0 to -2.0 mg/dL reduction | clinical guideline | KDIGO. Kidney Int Suppl. 2017;7:1-59.… |
| Serum Phosphate | clinical | Advanced renal failure with loss of phosphaturic response | +2.0 to +5.0 mg/dL severe hyperphosphatemia (>5.5 mg/dL) | prospective cohort | Block GA, et al. J Am Soc Nephrol. 2004;15:2208-2218.… |
| Serum Phosphate | diet | Strict elimination of inorganic phosphate food additives and dark sodas | -0.6 to -1.2 mg/dL reduction | rct | Sullivan C, et al. JAMA. 2009;301:629-635.… |
| Serum Phosphate | diet | High intake of ultra-processed meats and fast foods loaded with inorganic phosphate salts | +0.5 to +1.5 mg/dL elevation | prospective cohort | Ritz E, et al. Dtsch Arztebl Int. 2012;109:49-55.… |
| Serum Phosphate | pharmacologic | Non-calcium phosphate binders (Sevelamer carbonate / Lanthanum) | -1.5 to -2.5 mg/dL reduction in CKD hyperphosphatemia | rct | Chertow GM, et al. Kidney Int. 2002;62:245-252.… |
| Serum Potassium | diet | Potassium-rich whole food diet (vegetables, fruits, legumes: 3500-4700 mg/day) | Maintains optimal serum potassium within narrow 4.0-4.8 mmol/L band | RCT | National Center for Health Statistics. National Health and Nutrition E… |
| Serum Potassium | diet | DASH diet rich in potassium from fruits and leafy vegetables (3.5-4.7 g/day) | +0.3 to +0.6 mEq/L optimization from hypokalemic baseline | rct | Appel LJ, et al. N Engl J Med. 1997;336:1117-1124.… |
| Serum Potassium | pharmacologic | Novel non-absorbed potassium binders (Patiromer / Sodium Zirconium Cyclosilicate) | -0.7 to -1.2 mEq/L reduction in hyperkalemia | rct | Weir MR, et al. N Engl J Med. 2015;372:211-221.… |
| Serum Potassium | pharmacologic | Mineralocorticoid Receptor Antagonist titration (Spironolactone 25mg) | +0.3 to +0.5 mEq/L elevation preventing hypokalemia in heart failure | rct | Pitt B, et al. N Engl J Med. 1999;341:709-717.… |
| Serum Potassium | pharmacologic | Combined RAAS inhibitors and potassium-sparing agents in advanced CKD | +1.0 to +2.5 mEq/L severe hyperkalemia (>5.5 mEq/L) | rct | Fried LF, et al. N Engl J Med. 2013;369:1892-1903.… |
| Serum Potassium | pharmacologic | High-dose loop diuretics without potassium replacement | -0.8 to -1.5 mEq/L arrhythmogenic hypokalemia (<3.5 mEq/L) | systematic review | Gennari FJ. N Engl J Med. 1998;339:451-458.… |
| Serum Sodium | clinical | Fluid restriction (1.0-1.5 L/day) in syndrome of inappropriate ADH secretion (SIADH) | +3 to +6 mEq/L increase towards normal range | clinical guideline | Spasovski G, et al. Eur J Endocrinol. 2014;170:G1-G47.… |
| Serum Sodium | clinical | Severe unreplaced water loss and hypertonic dehydration | +10 to +25 mEq/L dangerous hypernatremia (>150 mEq/L) | clinical guideline | Adrogue HJ, et al. N Engl J Med. 2000;342:1493-1499.… |
| Serum Sodium | diet | Adequate fluid hydration and moderate dietary sodium intake (1500-2300 mg/day) | Stabilizes serum sodium in optimal 138-142 mmol/L range | cohort | National Center for Health Statistics. National Health and Nutrition E… |
| Serum Sodium | diet | Balanced dietary sodium (2.0-3.0 g/day) and hydration management | Maintains optimal eunatremic baseline (138-142 mEq/L) | meta-analysis | Mente A, et al. Lancet. 2018;392:496-506.… |
| Serum Sodium | pharmacologic | Vasopressin V2 receptor antagonists (Tolvaptan) in hypervolemic / euvolemic hyponatremia | +4 to +8 mEq/L normalization | rct | Schrier RW, et al. N Engl J Med. 2006;355:2099-2112.… |
| Serum Sodium | pharmacologic | Thiazide diuretic induced hyponatremia | -5 to -15 mEq/L drop (<130 mEq/L) | systematic review | Barber J, et al. J Clin Endocrinol Metab. 2014;99:3497-3504.… |
| Serum Total Bilirubin | clinical | Biliary decompression and stent placement in obstructive jaundice | -60% to -90% rapid clearance in obstructive hyperbilirubinemia | clinical guideline | Dumonceau JM, et al. Endoscopy. 2018;50:910-930.… |
| Serum Total Bilirubin | clinical | Decompensated liver cirrhosis or acute liver failure | +300% to +2000% toxic elevation (>3.0 mg/dL) | clinical guideline | Bernal W, et al. Lancet. 2010;376:190-201.… |
| Serum Total Bilirubin | clinical | Severe intravascular autoimmune hemolytic anemia | +150% to +500% indirect bilirubin elevation | systematic review | Packman CH. Blood Rev. 2008;22:1-16.… |
| Serum Total Bilirubin | exercise | Regular moderate aerobic exercise and maintenance of healthy body composition | Optimizes physiologic bilirubin in protective 0.6-1.1 mg/dL range | cohort | National Center for Health Statistics. National Health and Nutrition E… |
| Serum Total Bilirubin | lifestyle | Moderate aerobic exercise conditioning and dietary zinc optimization | Preserves optimal physiological 0.6-0.9 mg/dL antioxidant level | meta-analysis | Horsfall LJ, et al. J Am Heart Assoc. 2014;3:e001087.… |
| Serum Total Bilirubin | physiological | Mild benign hyperbilirubinemia (Gilbert syndrome phenotype / UGT1A1*28) | +0.4 to +0.8 mg/dL physiological elevation confers cardiovascular protection | prospective cohort | Vitek L, et al. Atherosclerosis. 2002;160:449-456.… |
| Serum Triglycerides | clinical | Uncontrolled Type 2 Diabetes and severe insulin resistance | +50% to +300% elevation (often >500 mg/dL, pancreatitis risk) | clinical guideline | Berglund L, et al. J Clin Endocrinol Metab. 2012;97:2969-2989.… |
| Serum Triglycerides | diet | Carbohydrate restriction, elimination of added sugars/alcohol, and Omega-3 EPA/DHA intake | Lowers triglycerides by 25-50% | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Serum Triglycerides | diet | Carbohydrate restriction and ketogenic / low-glycemic dietary protocol | -30% to -55% reduction | meta-analysis | Bueno NB, et al. Br J Nutr. 2013;110:1178-1187.… |
| Serum Triglycerides | diet | Excessive intake of alcohol and high-fructose corn syrup | +40% to +150% elevation | prospective cohort | Stanhope KL, et al. J Clin Invest. 2009;119:1322-1334.… |
| Serum Triglycerides | exercise | Aerobic and resistance exercise with 5-10% body weight loss | -20% to -40% reduction | rct | Wing RR, et al. Diabetes Care. 2011;34:1481-1486.… |
| Serum Triglycerides | pharmacologic | Icosapent ethyl (Purified EPA 4g/day) | -25% to -35% reduction with 25% MACE reduction | rct | Bhatt DL, et al. N Engl J Med. 2019;380:11-22.… |
| Serum Uric Acid | diet | Elimination of high-fructose corn syrup beverages and reduction of high-purine meats/beer | Lowers serum uric acid by 0.8-1.5 mg/dL | meta-analysis | Perlstein TS, et al. Serum uric acid and the risk of hypertension and … |
| Serum Uric Acid | diet | Elimination of high-fructose corn syrup beverages and beer | -10% to -25% reduction (0.8-1.8 mg/dL) | prospective cohort | Choi HK, et al. BMJ. 2008;336:309-312.… |
| Serum Uric Acid | diet | Heavy alcohol consumption, particularly beer and spirits | +25% to +50% elevation | prospective cohort | Choi HK, et al. Lancet. 2004;363:1277-1281.… |
| Serum Uric Acid | nutraceutical | Vitamin C supplementation (500-1000 mg/day) | -0.5 to -1.0 mg/dL reduction via uricosuric action | meta-analysis | Juraschek SP, et al. Arthritis Care Res. 2011;63:1295-1306.… |
| Serum Uric Acid | pharmacologic | Xanthine oxidase inhibitor therapy (Allopurinol 100-300 mg/day or Febuxostat) | Lowers serum uric acid by 2.0-4.0 mg/dL (35-55%) | RCT | Perlstein TS, et al. Serum uric acid and the risk of hypertension and … |
| Serum Uric Acid | pharmacologic | Xanthine oxidase inhibitors (Allopurinol 100-300 mg / Febuxostat 40-80 mg) | -35% to -55% reduction (2.5-4.5 mg/dL drop) | rct | Becker MA, et al. N Engl J Med. 2005;353:2450-2461.… |
| Serum Uric Acid | pharmacologic | Thiazide and loop diuretic therapy without uricosuric co-therapy | +1.0 to +2.5 mg/dL elevation | systematic review | Ben Salem C, et al. Pharmacoepidemiol Drug Saf. 2017;26:578-583.… |
| Systolic Blood Pressure (SBP) | diet | DASH diet (high potassium, magnesium, calcium, low sodium <2000 mg/day) | Reduces systolic BP by 8-14 mmHg | RCT | Rapsomaniki E, et al. Blood pressure and risk of vascular disease: 1.2… |
| Systolic Blood Pressure (SBP) | diet | DASH Dietary Pattern combined with sodium reduction (<1500 mg/day) | -8 to -14 mmHg systolic reduction | rct | Sacks FM, et al. N Engl J Med. 2001;344:3-10.… |
| Systolic Blood Pressure (SBP) | diet | High sodium intake (>5000 mg/day) and heavy alcohol bingeing | +10 to +20 mmHg systolic elevation | meta-analysis | He FJ, et al. BMJ. 2013;346:f1325.… |
| Systolic Blood Pressure (SBP) | exercise | Isometric resistance training and continuous aerobic endurance training | Reduces resting systolic BP by 5-10 mmHg | meta-analysis | Rapsomaniki E, et al. Blood pressure and risk of vascular disease: 1.2… |
| Systolic Blood Pressure (SBP) | exercise | Isometric exercise training and regular aerobic exercise (150 min/wk) | -5 to -10 mmHg systolic reduction | meta-analysis | Edwards JJ, et al. Br J Sports Med. 2023;57:1317-1326.… |
| Systolic Blood Pressure (SBP) | pharmacologic | First-line antihypertensive dual combination (ACEi/ARB + DHP-CCB or Thiazide) | -15 to -25 mmHg systolic reduction | rct | Jamerson K, et al. N Engl J Med. 2008;359:2417-2428.… |
| Systolic Blood Pressure (SBP) | pharmacologic | Chronic sympathomimetic / NSAID / Stimulant usage | +5 to +15 mmHg systolic elevation | systematic review | Johnson AG, et al. Ann Intern Med. 1994;121:289-300.… |
| Total Cholesterol | clinical | Untreated primary hypothyroidism | +20% to +50% elevation via LDL receptor downregulation | clinical guideline | Garber JR, et al. Endocr Pract. 2012;18:988-1028.… |
| Total Cholesterol | diet | Dietary soluble viscous fiber (Beta-glucan / Psyllium 10-15g/day) | -5% to -12% reduction | meta-analysis | Brown L, et al. Am J Clin Nutr. 1999;69:30-42.… |
| Total Cholesterol | diet | High dietary saturated fat and industrial trans-fatty acids | +15% to +35% elevation | meta-analysis | Mensink RP, et al. Am J Clin Nutr. 2003;77:1146-1155.… |
| Total Cholesterol | nutraceutical | Plant sterols and stanols (2 g/day) | -8% to -14% reduction | meta-analysis | Plat J, et al. Atherosclerosis. 2019;288:149-160.… |
| Total Cholesterol | pharmacologic | HMG-CoA reductase inhibitors (Statins) | -25% to -45% reduction | meta-analysis | Baigent C, et al. Lancet. 2010;376:1670-1681.… |
| Tumor Necrosis Factor-alpha (TNF-alpha) | diet | Caloric restriction and anti-inflammatory polyphenol-rich dietary intake | Reduces TNF-alpha by 15-30% | RCT | Estruch R, et al. Primary Prevention of Cardiovascular Disease with a … |
| Tumor Necrosis Factor-alpha (TNF-alpha) | diet | Plant-based polyphenol-rich dietary intervention | -15% to -28% reduction | rct | Schwingshackl L, et al. Nutrition. 2015;31:1-12.… |
| Tumor Necrosis Factor-alpha (TNF-alpha) | diet | High-fat, high-glycemic Western diet driving endotoxemia | +40% to +75% elevation | rct | Ghanim H, et al. Diabetes Care. 2009;32:1645-1647.… |
| Tumor Necrosis Factor-alpha (TNF-alpha) | lifestyle | Sedentary lifestyle and prolonged physical inactivity | +25% to +45% elevation | prospective cohort | Pedersen BK. Physiol Rev. 2017;97:1269-1284.… |
| Tumor Necrosis Factor-alpha (TNF-alpha) | nutraceutical | High-dose Resveratrol supplementation (500 mg/day) | -12% to -20% reduction | meta-analysis | Haghighatdoost F, et al. Crit Rev Food Sci Nutr. 2019;59:1453-1463.… |
| Tumor Necrosis Factor-alpha (TNF-alpha) | pharmacologic | TNF inhibitors (Infliximab / Adalimumab / Etanercept) | -60% to -85% bioactivity reduction | rct | Feldmann M, et al. Annu Rev Immunol. 2001;19:163-196.… |
| Urinary Creatinine Concentration | clinical | Severe muscle wasting, advanced sarcopenia, and amputation | -40% to -70% low urinary creatinine (<600 mg/24hr) | prospective cohort | Baxmann AC, et al. Clin J Am Soc Nephrol. 2008;3:348-354.… |
| Urinary Creatinine Concentration | diet | High-protein omnivorous dietary pattern | +10% to +25% increase | rct | Perrone RD, et al. Clin Chem. 1992;38:1933-1953.… |
| Urinary Creatinine Concentration | exercise | Progressive resistance hypertrophy training increasing skeletal muscle mass | +15% to +30% increase in daily creatinine excretion | rct | Forbes GB, et al. Am J Clin Nutr. 1983;37:433-439.… |
| Urinary Creatinine Concentration | lifestyle | Extensive overhydration / water intoxication (spot dilution <20 mg/dL) | -60% to -90% spot concentration dilution | mechanistic | Kesteloot H, et al. Lancet. 1996;347:489-493.… |
| Urinary Creatinine Concentration | nutraceutical | Creatine monohydrate supplementation (5g/day) | +20% to +40% increase in total urinary creatinine excretion | rct | Persky AM, et al. J Clin Pharmacol. 2003;43:1025-1033.… |
| Urinary Flow Rate | clinical | Adequate oral and intravenous volume resuscitation in shock | Restores urine flow > 0.5 mL/kg/hr, preventing acute kidney injury | rct | Rivers E, et al. N Engl J Med. 2001;345:1368-1377.… |
| Urinary Flow Rate | clinical | Acute tubular necrosis or complete urinary tract outflow obstruction | Oliguria (<0.3 mL/min) or absolute anuria (<50 mL/day) | clinical guideline | Bellomo R, et al. Crit Care. 2004;8:R204-R212.… |
| Urinary Flow Rate | clinical | Severe uncompensated hypovolemic or septic shock | -80% to -100% collapse in urine output | clinical guideline | Rhodes A, et al. Intensive Care Med. 2017;43:304-377.… |
| Urinary Flow Rate | diet | High water intake (>2.5 L/day) in recurrent nephrolithiasis | +50% to +100% flow increase, reducing kidney stone recurrence by 55% | rct | Borghi L, et al. J Urol. 1996;155:839-843.… |
| Urinary Flow Rate | pharmacologic | SGLT2 inhibitors inducing mild osmotic natriuresis | +300 to +500 mL/day increase in initial daily urine volume | rct | Heerspink HJ, et al. Circulation. 2016;134:752-772.… |
| Urine Albumin-to-Creatinine Ratio (uACR) | clinical | Diabetic nephropathy with advanced podocytopathy | +300% to +3000% macroalbuminuria (>300-3000 mg/g) | clinical guideline | De Zeeuw D, et al. Kidney Int. 2004;65:2309-2320.… |
| Urine Albumin-to-Creatinine Ratio (uACR) | clinical | Uncontrolled malignant hypertension with glomerular hyperfiltration | +200% to +1000% elevation | prospective cohort | Yuyun MF, et al. Am J Hypertens. 2004;17:669-676.… |
| Urine Albumin-to-Creatinine Ratio (uACR) | pharmacologic | ACE inhibitors / Angiotensin Receptor Blockers (ARBs) or SGLT2 inhibitors | Reduces uACR by 30-50% (reversing microalbuminuria) | RCT | Chronic Kidney Disease Prognosis Consortium. Association of estimated … |
| Urine Albumin-to-Creatinine Ratio (uACR) | pharmacologic | SGLT2 inhibitors (Dapagliflozin / Empagliflozin) | -30% to -45% reduction in albuminuria | rct | Heerspink HJL, et al. Lancet Diabetes Endocrinol. 2016;4:393-406.… |
| Urine Albumin-to-Creatinine Ratio (uACR) | pharmacologic | ACE inhibitors / ARBs titrated to maximally tolerated doses | -35% to -50% reduction in uACR | rct | Brenner BM, et al. N Engl J Med. 2001;345:861-869.… |
| Urine Albumin-to-Creatinine Ratio (uACR) | pharmacologic | Non-steroidal MRA (Finerenone 10-20 mg) | -31% reduction in albuminuria in diabetic kidney disease | rct | Bakris GL, et al. N Engl J Med. 2020;383:2219-2229.… |
| Urine Specific Gravity | clinical | End-stage renal medullary destruction / isosthenuria | Fixed specific gravity at 1.010 unable to concentrate or dilute | clinical guideline | Rose BD, Post TW. Clinical physiology of acid-base and electrolyte dis… |
| Urine Specific Gravity | diet | Consistent daily fluid hydration (2.5-3.5 L/day water intake) | Maintains urine specific gravity in optimal euvolemic range (1.010-1.020) | cohort | National Center for Health Statistics. National Health and Nutrition E… |
| Urine Specific Gravity | environmental | Severe hypertonic dehydration and heat exhaustion | +0.015 to +0.025 elevation (USG > 1.030) | prospective cohort | Casa DJ, et al. J Athl Train. 2000;35:212-224.… |
| Urine Specific Gravity | exercise | Electrolyte and fluid replacement during heavy endurance exercise | Prevents hypersthenuric dehydration (USG > 1.030) | rct | Sawka MN, et al. Med Sci Sports Exerc. 2007;39:377-390.… |
| Urine Specific Gravity | lifestyle | Structured consistent hydration (2.5-3.5 L/day water intake) | Maintains optimal euhydrated USG (1.012-1.018) | rct | Armstrong LE, et al. Int J Sport Nutr Exerc Metab. 2010;20:471-479.… |
| Urine Specific Gravity | pharmacologic | Desmopressin (dDAVP) therapy in central diabetes insipidus | Increases hyposthenuric USG from <1.005 to >1.015 | clinical guideline | Fenske W, et al. N Engl J Med. 2018;379:428-439.… |
| White Blood Cell Count (WBC) | behavioral | Smoking cessation and reduction of visceral adiposity | Lowers elevated WBC count by 1.5-2.5 x 10^3 cells/uL into optimal 4.5-6.5 range | cohort | National Center for Health Statistics. National Health and Nutrition E… |
| White Blood Cell Count (WBC) | behavioral | Smoking cessation | -1.5 to -3.0 × 10³/µL drop towards non-smoker baseline | prospective cohort | Bain BJ. Br J Haematol. 1996;95:439-446.… |
| White Blood Cell Count (WBC) | clinical | Targeted treatment of chronic focal infections (dental / sinus) | -1.0 to -2.5 × 10³/µL normalization | systematic review | Tonetti MS, et al. N Engl J Med. 2007;356:911-920.… |
| White Blood Cell Count (WBC) | clinical | Severe acute bacterial infection or septic shock | +10.0 to +30.0 × 10³/µL marked leukocytosis (>15.0 × 10³/µL) | clinical guideline | Singer M, et al. JAMA. 2016;315:801-810.… |
| White Blood Cell Count (WBC) | diet | Anti-inflammatory Mediterranean diet and exercise | -0.8 to -1.8 × 10³/µL reduction | rct | Esposito K, et al. JAMA. 2004;292:1440-1446.… |
| White Blood Cell Count (WBC) | pharmacologic | Myelosuppressive chemotherapy or aplastic bone marrow failure | -3.0 to -5.5 × 10³/µL severe leukopenia / neutropenia (<1.5 × 10³/µL) | clinical guideline | Freifeld AG, et al. Clin Infect Dis. 2011;52:e56-e93.… |